CTNNB1 and neoplasm: The primary goal is to target activated CTNNB1 pathways or CTNNB1 mutations to induce immune infiltration and/or to target highly expressed VEGF to induce vessel normalisation, thus improving tumour hypoxia and facilitating higher immune infiltration.